In an animal model of spinal and bulbar muscular atrophy (SBMA), a single injection during the neonatal period was found to prevent neurodegeneration in adulthood. The mechanism involves an androgen receptor-targeting ASO that prevents abnormalities in the REST gene, thereby supp
2026-05-04
A “five-in-one agonist” that simultaneously activates five metabolic receptors demonstrated a superior weight-loss effect and a 6,898-fold increase in potency compared with existing drugs in preclinical studies. The compound is a single molecule combining GLP-1/GIP and PPAR agoni
2026-05-04
Daewoong Pharmaceutical’s Fexuclue has added an indication for Helicobacter pylori eradication, achieving an eradication rate 26 percentage points higher than existing treatment in patients with antibiotic-resistant infections. In a phase 3 clinical trial, Fexuclue combination th
2026-05-04
FutureChem has received approval from the Ministry of Food and Drug Safety for ProstaView Injection, a radiopharmaceutical for diagnosing metastatic prostate cancer. ProstaView is used in positron emission tomography (PET) to diagnose patients with recurrent or metastatic prostat
2026-05-04
Bionmedicines’ combination therapy for HER2-positive gastric cancer has been designated for FDA priority review after demonstrating a median overall survival of 26.4 months in a phase 3 trial. The results came from the “HERIZON-GEA-01” study, which showed improved survival compar
2026-05-03
The ‘USP2a-METTL16’ loop was found to amplify IL-6 signaling, accelerating inflammation in pulmonary arterial hypertension. The loop acts by stabilizing IL-6 receptor mRNA through N6-methyladenosine (m6A). The USP2a inhibitor ‘ML364’ alleviated pulmonary vascular remodeling in an
2026-05-03
The Aurora-A protein was found to induce sorafenib resistance by forming stress granules through phase separation. This is a new mechanism in which Aurora-A forms a ternary complex with RNA and the G3BP1/2 proteins to support cancer cell survival. The findings open the way for de
2026-05-03
BeiGene’s Tevimbra combination therapy has received FDA priority review designation as a first-line treatment for HER2-positive gastric cancer, demonstrating an overall survival (OS) of 26.4 months. In the phase 3 trial, the treatment extended survival by more than 7 months compa
2026-05-03
A mechanism by which ERα⁺ macrophages aid cancer cell bone metastasis by reducing T cells and suppressing the immune response has been identified for the first time. In an animal model, removing the gene inhibited cancer cell colonization of bone and promoted T-cell infiltration.
2026-05-03
Loss of the UFL1 protein has been identified as a key factor that worsens prostate cancer and has been confirmed to cause chromosomal instability. UFL1 acts as a “quality inspector” during cell division; without the protein, errors in chromosome segregation occur, accelerating ca
2026-05-03
Peptone nears end of two-year Lilly technology evaluation…follow-on deal could be pivotal
HLB Pharmaceutical Completes 60.8 Billion Won Rights Offering, Bets on New Hyangnam Plant as Management Participation Grows
Song Young-sook sells 86 billion won stake; buyer is daughter’s one-person company — Is a second round of Hanmi control battle looming?
